Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
01
07
2022
revised:
06
10
2022
accepted:
28
11
2022
pubmed:
2
12
2022
medline:
3
2
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined with the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response and improve outcomes in recurrent/metastatic HPV-16/18-associated HNSCC. In this phase Ib/IIa study, immunotherapy-naïve patients with ≥1 previous platinum-containing regimen (neoadjuvant/adjuvant therapy or for recurrent/metastatic disease) received MEDI0457 7 mg intramuscularly with electroporation on weeks 1, 3, 7, and 12, then every 8 weeks, plus durvalumab 1,500 mg intravenously on weeks 4, 8, and 12, then every 4 weeks, until confirmed progression and/or unacceptable toxicity. Coprimary objectives were safety and objective response rate (ORR; H0: ORR ≤ 15%); secondary objectives included 16-week disease control rate (DCR-16), overall survival (OS), and progression-free survival (PFS). Of 35 treated patients, 29 were response evaluable (confirmed HPV-associated disease; received both agents). ORR was 27.6% [95% confidence interval (CI), 12.7-47.2; four complete responses, four partial responses]; responses were independent of PD-L1 tumor-cell expression (≥25% vs. <25%). DCR-16 was 44.8% (95% CI, 26.5-64.3). Median PFS was 3.5 months (95% CI, 1.9-9.0); median OS was 29.2 months (15.2-not calculable). Twenty-eight (80.0%) patients had treatment-related adverse events [grade 3: 5 (14.3%); no grade 4/5], resulting in discontinuation in 2 (5.7%) patients. HPV-16/18-specific T cells increased on treatment; 4 of 8 evaluable patients had a >2-fold increase in tumor-infiltrating CD8+ T cells. MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.
Identifiants
pubmed: 36455147
pii: 711368
doi: 10.1158/1078-0432.CCR-22-1987
pmc: PMC9890138
doi:
Substances chimiques
durvalumab
28X28X9OKV
MEDI0457
0
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-570Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Eur J Cancer. 2019 Mar;109:154-161
pubmed: 30731276
J Clin Med. 2018 Aug 27;7(9):
pubmed: 30150513
J Immunother. 2017 Feb/Mar;40(2):62-70
pubmed: 28166181
Front Mol Biosci. 2021 Jun 23;8:677900
pubmed: 34250016
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Front Immunol. 2018 Apr 23;9:830
pubmed: 29740440
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Treat Rev. 2019 Aug;78:8-16
pubmed: 31302573
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Mol Cancer Res. 2022 Jun 3;20(6):983-995
pubmed: 35302641
Sci Transl Med. 2012 Oct 10;4(155):155ra138
pubmed: 23052295
Oncoimmunology. 2014 Dec 21;3(11):e962401
pubmed: 25941589
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Cancer Immunol Res. 2020 Feb;8(2):246-254
pubmed: 31852717
Semin Oncol. 2015 Aug;42(4):587-600
pubmed: 26320063
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
J Vis Exp. 2014 Mar 11;(85):
pubmed: 24637627
J Clin Microbiol. 2006 Sep;44(9):3292-8
pubmed: 16954263
Front Oncol. 2021 Aug 17;11:730412
pubmed: 34490123
Nature. 2021 Sep;597(7875):274-278
pubmed: 33208941
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Res. 2014 Aug 1;74(15):4042-52
pubmed: 24812273
Nature. 2021 Sep;597(7875):279-284
pubmed: 34471285
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Clin Cancer Res. 2019 Jan 1;25(1):110-124
pubmed: 30242022
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
Cancers (Basel). 2021 Nov 30;13(23):
pubmed: 34885150
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
J Clin Oncol. 2016 Apr 20;34(12):1330-8
pubmed: 26926680
Cancer Immunol Res. 2015 Sep;3(9):1052-62
pubmed: 25943534
Cancers (Basel). 2021 Nov 23;13(23):
pubmed: 34884999
Clin Cancer Res. 2020 Jun 15;26(12):2827-2837
pubmed: 32376655
Front Immunol. 2019 Apr 02;10:653
pubmed: 31001266
N Engl J Med. 2007 May 10;356(19):1915-27
pubmed: 17494925